## Glenmark Pharmaceuticals Limited (GLENMARK) Stock Analysis

This report analyzes the provided data for Glenmark Pharmaceuticals Limited (GLENMARK) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                               |
|-----------------|------------------------------------|
| Symbol           | GLENMARK                           |
| Company Name     | Glenmark Pharmaceuticals Limited    |
| Industry         | Pharmaceuticals                     |
| ISIN             | INE935A01035                        |
| Listing Date     | 2000-02-07                          |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|------------|
| Last Price            | 1,545.00   |
| Change                | 4.20       |
| % Change              | 0.27%      |
| Previous Close        | 1,540.80   |
| Open                  | 1,530.05   |
| Close                 | 1,541.65   |
| VWAP                  | 1,546.06   |
| Week High             | 1,830.95   |
| Week Low              | 771.00     |
| Sector PE             | 0          |
| Symbol PE             | 0          |
| Delivery to Traded % | 50.55%     |
| Daily Volatility      | 1.92%      |
| Annual Volatility     | 36.68%     |


**1.3 Pre-Open Market Data:**

The pre-open market showed limited activity with a final price of 1,530.05, lower than the previous close.  Buy orders were significantly lower than sell orders.

**1.4 Corporate Actions:**

| Ex-Date       | Purpose                               | Dividend (Rs/Share) |
|---------------|---------------------------------------|----------------------|
| 13-Sep-2024   | Dividend                               | 2.50                 |
| 18-Sep-2023   | Dividend                               | 2.50                 |
| 12-Sep-2022   | Annual General Meeting/Dividend        | 2.50                 |
| 08-Sep-2021   | Annual General Meeting/Dividend        | 2.50                 |
| 17-Sep-2020   | Annual General Meeting/Dividend        | 2.50                 |
| 19-Sep-2019   | Annual General Meeting/Dividend        | 2.00                 |
| 19-Sep-2018   | Annual General Meeting/Dividend        | 2.00                 |
| 20-Sep-2017   | Annual General Meeting/Dividend        | 2.00                 |
| ...            | ...                                   | ...                   |


**1.5 Recent Announcements:**

* Multiple press releases and announcements related to acquisitions.
* Announcements regarding analysts' meetings and investor calls.
* Announcement of loss of share certificates.


**1.6 Financial Results (Last Five Quarters):**

| Quarter End     | Income (Rs)     | Expenditure (Rs) | Profit After Tax (Rs) | EPS (Rs) |
|-----------------|-----------------|--------------------|-----------------------|----------|
| 30-Sep-2024     | 271,917,600     | 192,411,700       | 59,505,600            | 21.09    |
| 30-Jun-2024     | 238,518,500     | 176,687,100       | 45,373,100            | 16.08    |
| 31-Mar-2024     | 293,449,300     | 178,656,100       | 461,369,500           | 163.50   |
| 31-Dec-2023     | 162,391,100     | 167,413,000       | -2,040,900            | -0.72    |
| 30-Sep-2023     | 227,963,300     | 187,059,800       | 30,235,400            | 10.72    |


**1.7 Shareholding Patterns:**

Promoter holding has remained relatively stable around 46.65% over the last four quarters.


**1.8 Key Directors and Contact Information:**

(Data provided in the original JSON is used here.  A more formatted table could be created if needed.)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price (1,545.00) is slightly above the previous close (1,540.80) and significantly below the week high (1,830.95) but above the week low (771.00).  Pre-open activity indicated a lower opening price.

**2.2 Financial Performance:**

Revenue shows some fluctuation, but generally positive growth over the last five quarters. Profitability is inconsistent, with a significant loss in Q4 2023. EPS is highly volatile.  The March 2024 quarter shows an unusually high EPS, which needs further investigation to understand the underlying reasons.

**2.3 Shareholding Analysis:**

Promoter shareholding remains consistent, indicating stability in the company's management.

**2.4 Corporate Action Summary:**

Consistent dividend payments over several years suggest a commitment to shareholder returns.

**2.5 Volatility and Risk:**

High annual volatility (36.68%) suggests a relatively risky investment.

**3. Final Verdict:**

**Don't Buy.**

**Reasoning:**

While the company shows some positive revenue growth and consistent dividend payments, the significant volatility, inconsistent profitability (including a substantial loss in Q4 2023), and the unusually high EPS in Q1 2024 raise significant concerns.  The high annual volatility further increases the risk profile.  Further investigation is needed to understand the reasons behind the volatile EPS and the Q4 2023 loss before considering an investment.  The data provided does not support a "Buy" recommendation with high confidence.

**Conclusion:**

Based on the provided financial data and market indicators, Glenmark Pharmaceuticals Limited presents a high-risk investment at this time.  The inconsistent profitability and high volatility outweigh the positive aspects of consistent dividend payments and relatively stable promoter holdings.  More information is needed to assess the long-term prospects of the company.
